Sebi Bars Seven Entities for Stock Manipulation via Social Media Freezes 20 Crore Gains UK Exports to US Plunge 25 as Trump Tariffs Reshape Trade Flows Mortgage and Refinance Rates Continue Downward Trend on May 23 2026 BT Warns of Potential Increases in Smartphone Prices Citing Industry Pressures Crude Oil Prices Retreat Amid Bearish Technical Pattern FatPipe FATN Valuation Raised to 640 by Zacks SmallCap Research After Preliminary Q4 Business Update Golden Entertainment GDEN Q4 2025 Earnings Steep Earnings Miss Amid Operational Challenges FCRX Q1 2026 Earnings Narrow Miss on EPS Stable Note Performance CRIS Q1 2026 Earnings Significant EPS Miss as Biotech Advances Pipeline Without Revenue MGEE Q1 2026 Earnings EPS Surpasses Estimates on Strong Utility Performance CME Q1 2026 Earnings EPS Slightly Misses Consensus as Shares Edge Higher RPT Q1 2026 Earnings Significant EPS Miss Stock Declines Skeena Resources Slips 35 as Bearish Pressure Tests Key Support Levels SKE Rafael Holdings RFL Edges Higher Testing Key Resistance After 219 Gain Kayne Anderson Energy Infrastructure Fund KYN Edges Lower Key Levels in Focus MarketAxess MKTX Gains Ground as Trading Volume Stabilizes Key Resistance Ahead enGene Holdings Inc ENGN Gains 349 as Stock Approaches Key Resistance Navios Maritime Partners LP Provides Operational Update in Q1 2026 Earnings Call UVV Q1 2026 Earnings EPS Misses Estimates Amid Challenging Market Conditions Xenetic Biosciences XBIO Bounces 303 Holding Above Key Support ATYR Q1 2026 Earnings NarrowerThanExpected Loss as Clinical Milestones Approach ARI Q1 2026 Earnings Earnings Miss by 20 as Credit Costs Weigh Stock Edges Higher TPG Mortgage Investment Trust Inc MITT Q1 2026 Earnings EPS Beats Estimates Amid Steady Portfolio Performance GEO Q1 2026 Earnings EPS Surprises to the Upside Despite Flat Revenue Disclosure THM Q1 2026 Earnings Modest Profit Reported Amid No Revenue and Market Pullback QRHC Q1 2026 Earnings EPS Misses Estimates Stock Gains Despite Loss TEVA Q1 2026 Earnings EPS Beats Estimates by 878 as Generic Drugmaker Posts Strong Quarter